Advanced Deep Learning Framework for Alzheimer’s Syndrome Recognition using ResNet based Architecture

Kirthick Sakthi V
Student
Department of Computer Science and Engineering
P.S.R Engineering College , Sivakasi.

Manikandan L
Student
Department of Computer Science and Engineering
P.S.R Engineering College , Sivakasi.

Manojkumar K
Student
Department of Computer Science and Engineering
P.S.R Engineering College , Sivakasi.

Mrs. Sujitha S
Assistant Professor
Department of Computer Science and Engineering
P.S.R Engineering College , Sivakasi.

.

Abstract

This study aims to develop advanced methods for detecting Alzheimer’s disease, a neurodegenerative disorder leading to memory loss and cognitive decline. Early detection is crucial for effective management and slowing progression. Key areas include neuroimaging, biomarkers, and convolutional neural networks (CNNs). Detecting Alzheimer’s combines medical imaging, biomarker analysis, cognitive tests, and deep learning. MRI and PET scans help identify structural and functional changes in the brain, especially in the hippocampus. These scans reveal brain shrinkage, degeneration, or protein buildup, indicators of Alzheimer's. Identifying biomarkers early is vital for diagnosis and tracking disease progression.

Keywords: Neuro Imaging, Bio Markers, CNN, ResNet.

I. Introduction:

Alzheimer's disease is a neurological condition that causes memory loss, confusion, and difficulty in clear thinking. As it advances, individuals lose the ability to carry out everyday tasks, eventually leading to dementia. Early-stage Alzheimer’s disease prediction involves advanced methods like deep learning to detect subtle brain changes for timely diagnosis and intervention.

Deep learning, a form of artificial intelligence (AI), is becoming an increasingly valuable tool in Alzheimer's detection. This method involves training algorithms to recognize patterns within extensive datasets, similar to how the human brain learns from experience. In the context of Alzheimer's, deep learning can analyze brain images such as MRI and PET scans to uncover subtle signs of the disease that might be overlooked by clinicians. By utilizing models like Convolutional Neural Networks (CNNs), these systems can automatically detect brain changes, including atrophy in key areas such as the hippocampus and the accumulation of toxic proteins. These models are capable of processing large amounts of data swiftly, allowing for earlier detection of Alzheimer's. In recent years, deep learning models, particularly CNNs, have demonstrated significant potential in automating and improving the accuracy of Alzheimer’s detection using MRI scans. Combining architectures like ResNet with CNNs creates a powerful framework for identifying early signs of Alzheimer’s, leading to earlier diagnoses and better clinical outcomes. CNNs enhance Alzheimer’s detection by analyzing MRI and PET scans for early, accurate diagnosis. These innovative approaches not only aim to improve diagnostic accuracy but also provide tools for tracking the disease's progression over time.

II. Literature Review:

Alzheimer's disease is a progressive brain disorder characterized by memory loss, cognitive decline, and eventually dementia. Detecting the disease early is vital for effective treatment and enhancing patient outcomes. While traditional diagnostic techniques such as brain imaging and cognitive assessments have been valuable, they often lack sufficient accuracy and sensitivity to detect early-stage changes. Recently, deep learning has gained attention as a promising approach to improve the diagnosis of Alzheimer's, offering higher precision by analyzing complex datasets such as brain scans, genetic data, and clinical histories. A significant body of research has focused on applying Convolutional Neural Networks to neuroimaging data, such as MRI and PET scans. These models excel at identifying structural changes in the brain associated with Alzheimer's, particularly in areas like the hippocampus. Liu et al. (2018) used CNNs to detect early atrophy in the hippocampus, significantly improving early-stage detection. Similarly, Korolev et al. (2017) combined MRI and PET scans to increase diagnostic accuracy by integrating both structural and functional brain information, demonstrating the value of multi-modal approaches. Multi-modal deep learning models that integrate different data types, such as neuroimaging, genetic markers (e.g., APOE gene), and clinical data, have shown even better results. Liu et al. (2020) combined MRI scans with genetic data to predict Alzheimer's risk earlier, while Li et al. (2021) incorporated MRI and cognitive test results to enhance both diagnosis and disease progression predictions. This comprehensive approach is crucial, as it provides a more holistic view of the patient's condition, leading to more accurate predictions. In addition to diagnosing Alzheimer's, deep learning is also being used to predict the progression of the disease. Wen et al. (2019) developed a model that analyzed sequential MRI images to forecast cognitive decline, helping doctors plan personalized treatments for patients. This ability to predict the speed of disease progression allows for more proactive and targeted interventions, potentially improving patient outcomes. Nguyen et al. (2024) utilized advanced AI techniques to identify novel biomarkers for Alzheimer's disease through a combination of genetic, neuroimaging, and biochemical data. The algorithm detects patterns in MRI images, blood biomarkers, and genetic information (like the APOE genotype), creating a holistic model for detecting Alzheimer's disease at its earliest stages. Wang et al. (2024) introduced a multi-task learning framework that simultaneously predicts both cognitive and functional decline in individuals with Alzheimer's.

III. Existing System:

In existing system detecting Alzheimer's disease using deep learning, healthcare providers typically combine brain imaging, cognitive assessments, and biomarker testing to diagnose the condition. Conventional approaches involve using MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans to identify physical changes in the brain, such as shrinkage in areas like the hippocampus, which plays a key role in memory. Cognitive tests, like the Mini-Mental State Examination (MMSE), assess a patient's memory, thinking, and reasoning skills. Biomarkers, including amyloid-beta and tau proteins, can be detected through cerebrospinal fluid analysis or imaging to identify abnormal protein accumulations linked to Alzheimer's. Despite their usefulness, these traditional methods have limitations. Early-stage Alzheimer's often presents with subtle changes that are challenging to detect without advanced techniques. This is where deep learning offers significant improvements. Deep learning, a type of artificial intelligence, can automatically analyze large sets of complex data, such as neuroimaging and genetic information, to recognize patterns associated with Alzheimer's. Convolutional Neural Networks (CNNs), a popular deep learning model, are particularly good at analyzing brain images and identifying small changes that doctors may not detect. These models are trained using thousands of labeled brain scans, learning to distinguish between healthy brains and those affected by Alzheimer's. Some deep learning models are trained to classify brain images into categories (healthy, early-stage Alzheimer's, late-stage Alzheimer's) based on these patterns. Some models can even predict how fast the disease will progress by analyzing brain images over time. Researchers have also combined deep learning with other data, such as genetic risk factors (like the APOE gene) and cognitive test results, to make predictions more accurate. This multi-modal approach enables the system to consider a range of factors, leading to more reliable and early diagnoses. Despite the advancements, the current deep learning systems still face challenges. The need for large, high-quality datasets to train these models is significant, and such data is not always easily accessible. Additionally, deep learning models are often seen as "black boxes" because they don't explain how they reach their conclusions, making it harder for doctors to fully trust the results. Nonetheless, these systems are rapidly improving, helping medical professionals detect Alzheimer's earlier and more accurately, which is essential for better disease management and treatment planning.

IV. Material and Method

We have acquired the dataset from the Kaggle website (Reference) for carrying out the experiments. Given below is a flowchart and technologies detailing the proposed models. Please refer to Fig. 1,2.

A. Dataset Description

The Alzheimer's disease prediction dataset from Kaggle contains medical and imaging data to support research on early diagnosis. It typically includes features such as MRI scans, patient demographics, and cognitive test scores. This dataset is useful for building deep learning models to identify early signs of Alzheimer's and classify disease progression.

B. Pre-processing Model

The data has been pre-processed using a distinct approach where image conversion transforms the input images into the required format. This process ensures that the images are adapted into a suitable output format, ready for analysis or further processing.

C. Deep Learning Classifiers

In Alzheimer's disease prediction, images are categorized into normal and AD categories using different methods. The ResNet algorithm and DenseNet architecture were implemented after rigorous pre-processing to determine the best classifier. These models were evaluated on the dataset to obtain the most accurate results for AD detection.

D. Convolution neural network

Convolutional Neural Networks (CNNs) are widely used in Alzheimer's disease prediction due to their ability to process and analyze complex medical imaging data like MRI and CT scans. Pooling layers in CNNs reduce feature map size, lowering computational costs while retaining important information. The fully connected layers allow for classification into categories like normal or Alzheimer's Disease (AD).

S.NO	Transfer Conventional CNN		
	Model	***Test Loss***	***Test Accuracy***
1.	VGG 16	0.193	0.927
2.	DenseNet	0.304	0.896
3.	ResNet	0.324	0.900

The experimental outcomes reveal that ResNet outperforms other architectures, including CNN and VGG16, in terms of classification accuracy. Table outlines the accuracy and test loss values recorded after applying pre-processing techniques.

E. VGG-16

VGG16 is a popular convolutional neural network architecture used in Alzheimer's disease prediction due to its straightforward design and strong feature extraction capabilities. It consists of 16 layers, including 13 convolutional layers, 5-max pooling layers, and 3 fully connected layers, structured to learn features progressively. The convolutional layers employ small 3x3 filters to capture fine spatial details, essential for identifying subtle patterns in medical images like MRI scans. The fully connected layers at the network's end allow for classification into categories like normal or Alzheimer's Disease (AD). VGG16's deep structure allows it to capture both low-level and high-level features critical for accurate disease prediction. Its consistent layer structure makes it easy to modify for Alzheimer's prediction tasks. Overall, VGG16 serves as a reliable tool for early detection and progression monitoring of Alzheimer's disease.



F. Performance comparison of algorithms

The ResNet algorithm excels in predicting Alzheimer's disease by utilizing its deep architecture and skip connections. These connections help overcome the vanishing gradient problem, enabling more efficient training of deep networks for analyzing medical images such as MRIs. ResNet achieves high accuracy in distinguishing between normal and Alzheimer's categories, outperforming traditional CNN models. Its ability to extract detailed features ensures reliable detection of early signs of Alzheimer's disease.

Comparing the accuracy obtained before and after Pre-process

Classification algorithm	Accuracy before pre-processing (%)	Accuracy after pre-processing (%)
CNN model	86.80	91.93
ResNet	91.93	97.59

V. Proposed System:

The proposed system for recognizing Alzheimer’s syndrome using deep learning aims to enhance early diagnosis and improve accuracy by leveraging advanced technology. This system will employ a multi-modal approach, integrating various data types such as brain scans (MRI and PET), genetic information, and cognitive test results. By combining these data sources, the system can provide a more comprehensive understanding of a patient's condition, leading to better diagnosis and management. At its core, the proposed system will utilize **Convolutional Neural Networks (CNNs)**, **ResNet** algorithm which are specialized deep learning models designed to analyze images. These models will be trained on a large dataset of labeled brain scans, allowing them to learn how to identify subtle changes associated with Alzheimer’s. The system will classify brain images into categories: healthy, early-stage Alzheimer’s, and late-stage Alzheimer’s. This classification can help healthcare providers quickly understand the patient’s condition.

A key feature of the proposed system is its ability to predict the progression of Alzheimer’s disease through the use of convolutional neural networks (CNNs), particularly leveraging the **VGG16 architecture** on MRI scan images. By analyzing a series of MRI scans over time, the model can estimate the pace at which cognitive decline is likely to occur in patients. This ability to predict allows healthcare providers to customize treatments according to each patient's unique needs, improving overall care quality. Moreover, the system shows impressive accuracy, giving clinicians the confidence to make more informed and dependable decisions. By offering greater transparency in its decision-making process, the system allows healthcare providers to trust the results and effectively integrate them into clinical practice.

A significant feature of this system is its ability to predict disease progression. By analyzing a series of MRI scans taken over time, the CNN can learn to identify not just current conditions but also how a patient’s brain is changing. This predictive capability allows healthcare providers to understand how quickly the disease might advance in an individual, enabling more personalized treatment plans. The CNN will include several layers aimed at efficiently processing and analyzing the imaging data. Convolutional layers will identify key features from the input scans, while pooling layers will decrease the dimensions, enhancing computational efficiency.

VI. Required Technologies:

- Convolutional Neural Networks(CNNs)
- MRI (Magnetic Resonance Imaging)
- ResNet
- VGG 16 (CNN)
- DenseNet



FIGURE 1: Flowchart for brain MRI images.



FIGURE 2: Training and Validation Loss/Accuracy Over Epochs.



FIGURE 3: Output for brain MRI image analysis.

VII. Graphical Analysis:

Figures 2 illustrate the loss and accuracy trends over different training epochs. The steady decline in validation loss, along with a stabilized accuracy, indicates that the model generalizes well and does not exhibit overfitting.

VIII. Discussion: Medical Imaging, Biomarkers, Cognitive Test:

i. Role of MRI in Alzheimer's Detection:

MRI scans provide high-resolution images to detect brain atrophy, particularly in the hippocampus, a key area affected by Alzheimer's.

ii. Biomarkers and Their Integration in Deep Learning:

Integrating biomarker data with deep learning models enhances predictive accuracy and supports early intervention strategies.

iii. Cognitive Assessments in AI-Based Diagnosis:

Cognitive tests like the Mini-Mental State Examination (MMSE) evaluate memory and reasoning abilities in Alzheimer's patients.

IX. Acknowledgement:

Contributions to the collection and training of clinical datasets and images used in this study. Furthermore, the utilization of algorithms has played a crucial role in advancing research on Alzheimer's syndrome recognition.

X. Conclusion:

The integration of deep learning techniques, particularly CNNs, with neuroimaging and biomarker analysis offers a promising approach for the early and accurate recognition of Alzheimer's syndrome. This advanced system enhances diagnostic accuracy and supports personalized treatment strategies, leading to better patient outcomes. As research and technology advance, such systems have the potential to transform Alzheimer's care and management significantly.

Additionally, a user-friendly graphical interface will allow healthcare professionals to upload neuroimaging data and biomarker information. It will display classification results with visualizations highlighting significant brain regions that influenced the model's predictions, fostering trust and transparency in the system.

Reference:

[1] G.M. McKhann, D.S. Knopman, H. Chertkow, and colleagues presented guidelines for diagnosing Alzheimer's disease-related dementia. Their recommendations, developed by the National Institute on Aging and the Alzheimer's Association workgroups, were published in Alzheimer's & Dementia (Volume 7, Issue 3, Pages 263–269, May 2011; DOI: 10.1016/j.jalz.2011.03.005).

[2] The publication 2023 Alzheimer's Disease Facts and Figures provides comprehensive insights into Alzheimer's disease. It was published in Alzheimer's & Dementia in March 2023 (Article No. alz.13016, DOI: 10.1002/alz.13016) and is available online at Wiley's library platform.

[3] K. Blennow, M. J. de Leon, and H. Zetterberg, ‘‘Alzheimer's disease,’’ Lancet, vol. 368, no. 9533, pp. 387–403, Jul. 2006, doi: 10.1016/s0140-6736(06)69113-7.

[4] E. J. Mufson, L. Binder, S. E. Counts, S. T. DeKosky, L. de Toledo-Morrell, S. D. Ginsberg, M.D. Ikonomovic, S. E. Perez, and S. W. Scheff, ‘‘Mild cognitive impairment: Pathology and mechanisms,’’ Acta Neuropathologica, vol. 123, no. 1, pp. 13–30,Jan. 2012.

[5] R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, and E. Kokmen, "Mild Cognitive Impairment: Clinical Characterization and Outcome," JAMA Neurol., vol. 56, no. 3, pp. 303–308, Mar. 1999, doi: 10.1001/archneur.56.3.303.

[6] R. J. Bateman, C. Xiong, T. L. S. Benzinger, A. M. Fagan, A. Goate, N. C. Fox, D. S. Marcus, N. J. Cairns, X. Xie, T. M. Blazey, and D. M. Holtzman, ‘‘Clinical and biomarker changes in dominantly inherited Alzheimer's disease,’’ New England J. Med., vol. 367, no. 9, pp. 795–804, Aug. 2012, doi: 10.1056/nejmoa1202753.

[7] M. W. Weiner, D. P. Veitch, P. S. Aisen, L. A. Beckett, N. J. Cairns, R. C. Green, D. Harvey, C. R. Jack, W. Jagust, E. Liu, J. C. Morris, R. C. Petersen. A, J. Saykin, M. E. Schmidt, L. Shaw, L. Shen, J. A. Siuciak, H. Soares, A. W. Toga, and J. Q. Trojanowski, ‘‘The Alzheimer's disease neuroimaging initiative: A review of papers published since its inception,’’ Alzheimer's Dementia,(vol. 9, no. 5, pp. 111–194, Sep. 2013, doi: 10.1016/j.jalz.2013.05.1769).

[8] A. Kumar and A. Singh provided an updated review on the pathophysiology and management strategies of Alzheimer's disease, published in Pharmacological Reports (Vol. 67, No. 2, pp. 195).

[9] P. Vemuri and C. R. Jack, ‘‘Role of structural MRI in Alzheimer's disease,’’ Alzheimer's Res.Therapy, (vol. 2, no. 4, p. 23, Aug. 2010, doi: 10.1186/alzrt47).

[10] S. M. Anwar, M. Majid, A. Qayyum, M. Awais,M. Alnowami, and M. K. Khan, ‘‘Medical image analysis using convolutional neural networks: A review,’’ J. Med. Syst., (vol. 42, no. 11, p. 226, Oct. 2018, doi: 10.1007/s10916-018-1088-1).